Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Novo Nordisk announced company veteran Maziar Mike Doustdar as its next CEO, as the firm struggles to regain its dominance in ...

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief ...

Novo Nordisk, the maker of Wegovy, plans to cut costs and refocus commercially after a $95 billion stock loss. The company's market cap has dropped to around $212 billion.

Novo Nordisk has appointed Maziar Mike Doustdar as CEO, replacing Lars Fruergaard, to address recent market challenges.

Danish leader will face a challenging landscape among competitors ...

The GLP-1 weight-loss drug giant just cut its investor guidance for 2025. Could the boom be over? Health-related stocks are ...

July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...

Danish pharmaceutical giant Novo Nordisk on Tuesday named its new CEO and cut its full-year sales and profit guidance.

Maziar Mike Doustdar spent more than three decades quietly climbing the ranks of Novo Nordisk A/S, from office clerk through ...

Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...